SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Learning the interaction rules of antibody-antigen binding

This project aims to enhance antibody-antigen binding prediction by generating large-scale sequence and structural data through high-throughput screening and machine learning techniques.

Subsidie
€ 2.000.000
2024

Projectdetails

Introduction

Antibody-antigen binding is the basis of two fundamental biotherapeutic pillars: monoclonal antibodies (1) and vaccines (2). To accelerate therapeutics discovery, we need to perform antibody (Ab) and antigen (Ag) design in silico. Specifically, we need to address a fundamental immuno-biotechnological challenge: understanding the interaction rules that predict Ab-Ag binding. Solving this challenge demands the convergence of biotechnology, computational structural biology, and machine learning (ML). My lab is one of the few worldwide to have this transdisciplinary expertise.

Research Problem

Currently, the predictive performance of Ab-Ag binding is poor, and an understanding of the underlying rules of Ab-Ag binding is mostly absent. We previously showed that both unprecedentedly large datasets (>10^5 Ab-Ag sequence pairs) and extensive structural information on the Ab-Ag binding interface (paratope, epitope) are needed to increase prediction accuracy and recover binding rules.

Targeted Breakthrough

To address the lack of large-scale Ab-Ag sequence and structural data, we will develop a method for high-throughput screening of:

  1. 10^3 Ab paratope-mutated variants

  2. 10^3 Ag epitope-mutated variants

This will generate sequence data of Ab-Ag binding pairs at an unprecedented scale (>10^6 sequence Ab-Ag pairs). Structural information of the entirety of the sequence-based Ab-Ag binding data will be generated by building and innovating on recent breakthroughs in computational structural biology.

To derive Ab-Ag interaction rules from the generated data, we will develop ML techniques for Ab-Ag binding prediction and rule recovery. We will demonstrate experimentally that we have begun to understand Ab-Ag interaction rules.

Impact

The proposed research generates the exact data necessary to recover the rules of Ab-Ag binding and provides a first groundbreaking insight into those rules, moving us closer to in silico on-demand antibody and vaccine design.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.000.000
Totale projectbegroting€ 2.000.000

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITETET I OSLOpenvoerder

Land(en)

Norway

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Computational design of synthetic antibody repertoires for accelerated therapeutic discovery

CADABRE aims to design and optimize diverse human antibody repertoires with enhanced stability and developability for therapeutic discovery using advanced protein design and AI-driven screening methods.

ERC Advanced...€ 2.741.000
2024
Details

Structure and Function-based Design of Vaccine Antigens and Antiviral Immunotherapies

This project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses.

ERC Starting...€ 1.499.525
2025
Details

REVisiting Antibody structures and repertoires through advances in Mass spectrometry and Proteomics

REVAMP aims to develop innovative mass spectrometry techniques to comprehensively analyze the structural and functional diversity of human antibody repertoires, enhancing our understanding of immune responses.

ERC Advanced...€ 2.500.000
2025
Details

Computer aided de novo design of nanobodies

The project aims to automate the design of fully de novo nanobodies with nanomolar affinity using AI-driven methods, eliminating animal use and enhancing efficiency in antibody development.

ERC Proof of...€ 150.000
2024
Details

Immune Synapse Engagement as a Novel Approach for Cancer Immunotherapy

The project aims to develop bi- and multi-specific antibodies that enhance immune cell interactions to improve the efficacy of cancer immunotherapy by targeting T-cell-dendritic cell synapses.

ERC Consolid...€ 2.000.000
2023
Details
ERC Advanced...

Computational design of synthetic antibody repertoires for accelerated therapeutic discovery

CADABRE aims to design and optimize diverse human antibody repertoires with enhanced stability and developability for therapeutic discovery using advanced protein design and AI-driven screening methods.

ERC Advanced Grant
€ 2.741.000
2024
Details
ERC Starting...

Structure and Function-based Design of Vaccine Antigens and Antiviral Immunotherapies

This project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses.

ERC Starting Grant
€ 1.499.525
2025
Details
ERC Advanced...

REVisiting Antibody structures and repertoires through advances in Mass spectrometry and Proteomics

REVAMP aims to develop innovative mass spectrometry techniques to comprehensively analyze the structural and functional diversity of human antibody repertoires, enhancing our understanding of immune responses.

ERC Advanced Grant
€ 2.500.000
2025
Details
ERC Proof of...

Computer aided de novo design of nanobodies

The project aims to automate the design of fully de novo nanobodies with nanomolar affinity using AI-driven methods, eliminating animal use and enhancing efficiency in antibody development.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Consolid...

Immune Synapse Engagement as a Novel Approach for Cancer Immunotherapy

The project aims to develop bi- and multi-specific antibodies that enhance immune cell interactions to improve the efficacy of cancer immunotherapy by targeting T-cell-dendritic cell synapses.

ERC Consolidator Grant
€ 2.000.000
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Accelerated Discovery Nanobody Platform

The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.

EIC Pathfinder€ 3.315.441
2024
Details

Haalbaarheid van het Formula Y-platform voor versnelde antilichaam ontwikkeling

Het project richt zich op het versnellen van de ontwikkeling van nieuwe antilichaamtherapieën door generatieve machine-learning algoritmes te gebruiken voor het ontwerpen van specifieke antilichamen.

Mkb-innovati...€ 20.000
2023
Details

Precision control of glycosylation to open a new era of therapeutic antibodies

GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.

EIC Transition€ 2.499.540
2025
Details

From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody Development

Dit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker.

Mkb-innovati...€ 153.020
2020
Details
EIC Pathfinder

Accelerated Discovery Nanobody Platform

The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.

EIC Pathfinder
€ 3.315.441
2024
Details
Mkb-innovati...

Haalbaarheid van het Formula Y-platform voor versnelde antilichaam ontwikkeling

Het project richt zich op het versnellen van de ontwikkeling van nieuwe antilichaamtherapieën door generatieve machine-learning algoritmes te gebruiken voor het ontwerpen van specifieke antilichamen.

Mkb-innovatiestimulering Topsectoren Haalbaarheid
€ 20.000
2023
Details
EIC Transition

Precision control of glycosylation to open a new era of therapeutic antibodies

GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.

EIC Transition
€ 2.499.540
2025
Details
Mkb-innovati...

From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody Development

Dit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 153.020
2020
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.